US5549924A
(en)
|
1987-07-17 |
1996-08-27 |
Robin Renee Thill Shlenker |
Method of forming a membrane, especially a latex or polymer membrane, including a deactivating barrier and indicating layer
|
US5679399A
(en)
|
1987-07-17 |
1997-10-21 |
Bio Barrier, Inc. |
Method of forming a membrane, especially a latex or polymer membrane, including multiple discrete layers
|
US5314696A
(en)
*
|
1991-06-27 |
1994-05-24 |
Paulos Manley A |
Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor
|
WO1996010996A1
(en)
*
|
1993-07-21 |
1996-04-18 |
The University Of Kentucky Research Foundation |
A multicompartment hard capsule with control release properties
|
US5397574A
(en)
*
|
1993-10-04 |
1995-03-14 |
Andrx Pharmaceuticals, Inc. |
Controlled release potassium dosage form
|
FR2723536A1
(fr)
*
|
1994-08-11 |
1996-02-16 |
Seth Pawan |
Composition permettant une liberation selective d'un principe actif
|
US5567441A
(en)
*
|
1995-03-24 |
1996-10-22 |
Andrx Pharmaceuticals Inc. |
Diltiazem controlled release formulation
|
US20060068001A1
(en)
*
|
1996-03-25 |
2006-03-30 |
Wyeth |
Extended release formulation
|
US8071128B2
(en)
|
1996-06-14 |
2011-12-06 |
Kyowa Hakko Kirin Co., Ltd. |
Intrabuccally rapidly disintegrating tablet and a production method of the tablets
|
WO1998029095A2
(en)
*
|
1997-01-03 |
1998-07-09 |
Elan Corporation, Plc |
Sustained release cisapride mini-tablet formulation
|
JP3825811B2
(ja)
*
|
1997-01-14 |
2006-09-27 |
エルティエス ローマン テラピー−ズュステーメ アーゲー |
胃腸系での活性物質の制御放出を用いた膨張性胃内貯留治療システム
|
US5788987A
(en)
*
|
1997-01-29 |
1998-08-04 |
Poli Industria Chimica Spa |
Methods for treating early morning pathologies
|
US5840329A
(en)
*
|
1997-05-15 |
1998-11-24 |
Bioadvances Llc |
Pulsatile drug delivery system
|
MY125849A
(en)
*
|
1997-07-25 |
2006-08-30 |
Alza Corp |
Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
|
PT1021171E
(pt)
*
|
1997-10-09 |
2003-10-31 |
Dexcel Pharma Technologies Ltd |
Sistema de administracao de farmacos no tracto gastrointestinal de libertacao total prolongada
|
US6607751B1
(en)
*
|
1997-10-10 |
2003-08-19 |
Intellipharamaceutics Corp. |
Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
|
US20060141036A1
(en)
*
|
1997-12-12 |
2006-06-29 |
Andrx Labs Llc |
HMG-CoA reductase inhibitor extended release formulation
|
US5916595A
(en)
*
|
1997-12-12 |
1999-06-29 |
Andrx Pharmaceutials, Inc. |
HMG co-reductase inhibitor
|
US20040029962A1
(en)
*
|
1997-12-12 |
2004-02-12 |
Chih-Ming Chen |
HMG-COA reductase inhibitor extended release formulation
|
US6372254B1
(en)
*
|
1998-04-02 |
2002-04-16 |
Impax Pharmaceuticals Inc. |
Press coated, pulsatile drug delivery system suitable for oral administration
|
CA2507743C
(en)
*
|
1998-08-12 |
2008-03-18 |
Altana Pharma Ag |
Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
|
US6531152B1
(en)
|
1998-09-30 |
2003-03-11 |
Dexcel Pharma Technologies Ltd. |
Immediate release gastrointestinal drug delivery system
|
US20010055613A1
(en)
|
1998-10-21 |
2001-12-27 |
Beth A. Burnside |
Oral pulsed dose drug delivery system
|
US20090297597A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Gary Liversidge |
Modified Release Ticlopidine Compositions
|
DK1126826T6
(en)
*
|
1998-11-02 |
2019-06-24 |
Alkermes Pharma Ireland Ltd |
Multiparticulate modified release of methylphenidate
|
US20090149479A1
(en)
*
|
1998-11-02 |
2009-06-11 |
Elan Pharma International Limited |
Dosing regimen
|
US20080118556A1
(en)
*
|
1998-11-02 |
2008-05-22 |
Elan Corporation, Plc |
Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
|
US20070122481A1
(en)
*
|
1998-11-02 |
2007-05-31 |
Elan Corporation Plc |
Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
|
US20060240105A1
(en)
*
|
1998-11-02 |
2006-10-26 |
Elan Corporation, Plc |
Multiparticulate modified release composition
|
JP5558648B2
(ja)
|
1998-11-23 |
2014-07-23 |
デイビス、ボニー |
アセチルコリンエステラーゼ阻害剤のための投与製剤
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
US6210716B1
(en)
*
|
1999-02-26 |
2001-04-03 |
Andrx Pharmaceuticals, Inc. |
Controlled release bupropion formulation
|
US20030170181A1
(en)
*
|
1999-04-06 |
2003-09-11 |
Midha Kamal K. |
Method for preventing abuse of methylphenidate
|
AU4221300A
(en)
|
1999-04-06 |
2000-10-23 |
Kamal K. Midha |
Pharmaceutical dosage form for pulsatile delivery of (d-threo)-methylphenidate and a second cns stimulant
|
US6632451B2
(en)
|
1999-06-04 |
2003-10-14 |
Dexcel Pharma Technologies Ltd. |
Delayed total release two pulse gastrointestinal drug delivery system
|
GB9923045D0
(en)
*
|
1999-09-29 |
1999-12-01 |
Novartis Ag |
New oral formulations
|
NZ529928A
(en)
|
1999-10-29 |
2005-10-28 |
Euro Celtique Sa |
Controlled release hydrocodone formulations
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
DE60033864T2
(de)
*
|
1999-11-17 |
2007-11-22 |
Reckitt Benckiser (Uk) Limited, Slough |
Spritzgegossener wasserlöslicher Behälter
|
WO2001037811A1
(en)
*
|
1999-11-22 |
2001-05-31 |
Akzo Nobel N.V. |
Composition allowing predefined and controlled release of active ingredient, preparation thereof and use
|
US20060153914A1
(en)
*
|
1999-12-10 |
2006-07-13 |
Biovail Laboratories International S.R.L. |
Chronotherapeutic diltiazem formulations and the administration thereof
|
US7108866B1
(en)
|
1999-12-10 |
2006-09-19 |
Biovall Laboratories International Srl |
Chronotherapeutic diltiazem formulations and the administration thereof
|
JP2003518487A
(ja)
|
1999-12-23 |
2003-06-10 |
ファイザー・プロダクツ・インク |
ヒドロゲル駆動型積層薬物製剤
|
US6669954B2
(en)
|
2000-01-25 |
2003-12-30 |
John R. Crison |
Controlled release of drugs
|
US6627223B2
(en)
*
|
2000-02-11 |
2003-09-30 |
Eurand Pharmaceuticals Ltd. |
Timed pulsatile drug delivery systems
|
US6669948B2
(en)
|
2000-02-24 |
2003-12-30 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US6663891B2
(en)
|
2000-02-24 |
2003-12-16 |
Advancis Pharmaceutical Corp. |
Erythromyacin antibiotic product, use and formulation thereof
|
US6632453B2
(en)
|
2000-02-24 |
2003-10-14 |
Advancis Pharmaceutical Corp. |
Ciprofoxacin-metronidazole antibiotic composition
|
US6667042B2
(en)
|
2000-02-24 |
2003-12-23 |
Advancis Pharmaceutical Corp. |
Fluroquinilone antibiotic product, use and formulation thereof
|
US6991807B2
(en)
*
|
2000-02-24 |
2006-01-31 |
Advancis Pharmaceutical, Corp. |
Antibiotic composition
|
US6627222B2
(en)
|
2000-02-24 |
2003-09-30 |
Advancis Pharmaceutical Corp. |
Amoxicillin-dicloxacillin antibiotic composition
|
US6730320B2
(en)
|
2000-02-24 |
2004-05-04 |
Advancis Pharmaceutical Corp. |
Tetracycline antibiotic product, use and formulation thereof
|
AU2001239841B2
(en)
*
|
2000-02-24 |
2006-04-27 |
Shionogi, Inc. |
Antibiotic and antifungal compositions
|
US6638532B2
(en)
|
2000-02-24 |
2003-10-28 |
Advancis Pharmaceutical Corp. |
Tetracycline—doxycycline antibiotic composition
|
US6623758B2
(en)
*
|
2000-02-24 |
2003-09-23 |
Advancis Pharmaceutical Corp. |
Cephalosporin-metronidazole antibiotic composition
|
US6663890B2
(en)
|
2000-02-24 |
2003-12-16 |
Advancis Pharmaceutical Corp. |
Metronidazole antibiotic product, use and formulation thereof
|
US7025989B2
(en)
*
|
2000-02-24 |
2006-04-11 |
Advancis Pharmaceutical Corp. |
Multiple-delayed released antibiotic product, use and formulation thereof
|
AU2001239838A1
(en)
*
|
2000-02-24 |
2001-09-03 |
Advancis Pharmaceutical Corporation |
Therapeutic product, use and formulation thereof
|
US6565882B2
(en)
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
US6610328B2
(en)
|
2000-02-24 |
2003-08-26 |
Advancis Pharmaceutical Corp. |
Amoxicillin-clarithromycin antibiotic composition
|
US6667057B2
(en)
|
2000-02-24 |
2003-12-23 |
Advancis Pharmaceutical Corp. |
Levofloxacin antibiotic product, use and formulation thereof
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
WO2001062231A1
(en)
*
|
2000-02-24 |
2001-08-30 |
Advancis Pharmaceutical Corporation |
Antibiotic composition with inhibitor
|
US6551617B1
(en)
|
2000-04-20 |
2003-04-22 |
Bristol-Myers Squibb Company |
Taste masking coating composition
|
DK1276470T3
(da)
|
2000-04-20 |
2007-06-18 |
Novartis Ag |
Smagskaskerende overtrækssammensætning
|
US6500457B1
(en)
|
2000-08-14 |
2002-12-31 |
Peirce Management, Llc |
Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
|
US7074417B2
(en)
*
|
2000-10-13 |
2006-07-11 |
Advancis Pharmaceutical Corporation |
Multiple-delayed release anti-viral product, use and formulation thereof
|
US7157095B2
(en)
*
|
2000-10-13 |
2007-01-02 |
Advancis Pharmaceutical Corporation |
Multiple-delayed release antifungal product, use and formulation thereof
|
US7105174B2
(en)
*
|
2000-10-13 |
2006-09-12 |
Advancis Pharmaceutical Corporation |
Multiple-delayed release anti-neoplastic product, use and formulation thereof
|
US20020068078A1
(en)
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
US6541014B2
(en)
*
|
2000-10-13 |
2003-04-01 |
Advancis Pharmaceutical Corp. |
Antiviral product, use and formulation thereof
|
US7108859B2
(en)
*
|
2000-10-13 |
2006-09-19 |
Advancis Pharmaceutical Corporation |
Antineoplastic product, use and formulation thereof
|
KR101045144B1
(ko)
|
2000-10-30 |
2011-06-30 |
유로-셀티크 소시에떼 아노뉨 |
서방성 하이드로코돈 제형
|
US7964216B2
(en)
|
2001-01-12 |
2011-06-21 |
Sun Pharma Advanced Research Company Limited |
Spaced drug delivery system
|
US20020197314A1
(en)
|
2001-02-23 |
2002-12-26 |
Rudnic Edward M. |
Anti-fungal composition
|
US20030190360A1
(en)
*
|
2001-03-13 |
2003-10-09 |
Baichwal Anand R. |
Chronotherapeutic dosage forms containing glucocorticosteroid and methods of treatment
|
DK1377276T3
(da)
*
|
2001-04-10 |
2012-01-02 |
Sun Pharma Advanced Res Co Ltd |
Beregning af puls-frigivelsessammensætning
|
US6663896B1
(en)
|
2001-08-01 |
2003-12-16 |
Alvin S. Blum |
Delayed release aspirin for vascular obstruction prophylaxis
|
US9358214B2
(en)
*
|
2001-10-04 |
2016-06-07 |
Adare Pharmaceuticals, Inc. |
Timed, sustained release systems for propranolol
|
US6500454B1
(en)
*
|
2001-10-04 |
2002-12-31 |
Eurand Pharmaceuticals Ltd. |
Timed, sustained release systems for propranolol
|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
US20030104052A1
(en)
*
|
2001-10-25 |
2003-06-05 |
Bret Berner |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
CA2409552A1
(en)
*
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
US6635675B2
(en)
|
2001-11-05 |
2003-10-21 |
Cypress Bioscience, Inc. |
Method of treating chronic fatigue syndrome
|
US6602911B2
(en)
|
2001-11-05 |
2003-08-05 |
Cypress Bioscience, Inc. |
Methods of treating fibromyalgia
|
US20050163846A1
(en)
*
|
2001-11-21 |
2005-07-28 |
Eisai Co., Ltd. |
Preparation composition containing acid-unstable physiologically active compound, and process for producing same
|
US20050025824A1
(en)
*
|
2001-12-14 |
2005-02-03 |
Eurand Pharmaceuticals Ltd. |
Pulsatile release histamine H2 antagonist dosage form
|
US6663888B2
(en)
*
|
2001-12-14 |
2003-12-16 |
Eurand Pharmaceuticals Ltd. |
Pulsatile release histamine H2 antagonist dosage form
|
CA2469673A1
(en)
*
|
2001-12-19 |
2003-06-26 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Controlled release molded product
|
AU2002359768A1
(en)
*
|
2001-12-20 |
2003-10-27 |
Middlebrook Pharmaceuticals, Inc. |
Antibiotic product, use and formulation thereof
|
GB0130518D0
(en)
*
|
2001-12-21 |
2002-02-06 |
Univ Gent |
Pulsed bio-agent delivery systems based on degradable polymer solutions or hydrogels
|
US20060073204A1
(en)
*
|
2002-03-05 |
2006-04-06 |
Sandhya Goyal |
Modified release oral pharmaceutical composition
|
CA2478121A1
(en)
*
|
2002-03-07 |
2003-09-18 |
Advancis Pharmaceutical Corporation |
Antibiotic composition
|
US7670612B2
(en)
|
2002-04-10 |
2010-03-02 |
Innercap Technologies, Inc. |
Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
|
US6958161B2
(en)
|
2002-04-12 |
2005-10-25 |
F H Faulding & Co Limited |
Modified release coated drug preparation
|
AU2003256308B2
(en)
*
|
2002-06-26 |
2008-07-03 |
Intarcia Therapeutics, Inc. |
Minimally compliant, volume efficient piston for osmotic drug delivery systems
|
EP1519717B1
(de)
*
|
2002-07-05 |
2010-09-29 |
Temrel Limited |
Zusammensetzung zur kontrollierten wirkstoffabgabe
|
US6913768B2
(en)
*
|
2002-09-24 |
2005-07-05 |
Shire Laboratories, Inc. |
Sustained release delivery of amphetamine salts
|
US20080220074A1
(en)
*
|
2002-10-04 |
2008-09-11 |
Elan Corporation Plc |
Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
|
CA2406592C
(en)
*
|
2002-10-04 |
2003-09-30 |
Duchesnay Inc. |
Method of preparing pharmaceutical dosage forms containing multiple active ingredients
|
AU2003284942A1
(en)
*
|
2002-10-30 |
2004-06-07 |
Pharmacia Corporation |
Oral extended release tablets and methods of making and using the same
|
CN1849142A
(zh)
|
2002-11-15 |
2006-10-18 |
埃迪尼克斯(开曼)有限公司 |
2′-支链核苷和黄病毒突变
|
US6893660B2
(en)
*
|
2002-11-21 |
2005-05-17 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions without a stabilizer
|
US20040114368A1
(en)
*
|
2002-12-13 |
2004-06-17 |
Shyu Shing Jy |
Light device having rotatable or movable view
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
US8367111B2
(en)
|
2002-12-31 |
2013-02-05 |
Aptalis Pharmatech, Inc. |
Extended release dosage forms of propranolol hydrochloride
|
US7153526B2
(en)
*
|
2003-02-26 |
2006-12-26 |
Frank Steven R |
Treatment of gastrointestinal infections
|
US20060210633A1
(en)
*
|
2003-04-03 |
2006-09-21 |
Sun Pharmaceutical Industries Limited |
Programmed drug delivery system
|
MXPA05010636A
(es)
*
|
2003-04-04 |
2005-12-12 |
Pharmacia Corp |
Comprimidos de multiparticulas preparados por compresion de liberacion oral prolongada.
|
US8802139B2
(en)
|
2003-06-26 |
2014-08-12 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
CA2533178C
(en)
*
|
2003-07-21 |
2014-03-11 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
WO2005009364A2
(en)
|
2003-07-21 |
2005-02-03 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
CA2533292C
(en)
|
2003-07-21 |
2013-12-31 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
WO2005016311A1
(en)
|
2003-08-11 |
2005-02-24 |
Advancis Pharmaceutical Corporation |
Robust pellet
|
AU2004264356B2
(en)
*
|
2003-08-12 |
2011-01-27 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
JP5686494B2
(ja)
*
|
2003-08-29 |
2015-03-18 |
シオノギ インコーポレイテッド |
抗生物質製剤、その使用法及び作成方法
|
EP1663169A4
(de)
|
2003-09-15 |
2010-11-24 |
Middlebrook Pharmaceuticals In |
Antibiotisches produkt, seine verwendung und formulierung
|
US20050118267A1
(en)
*
|
2003-09-19 |
2005-06-02 |
Penwest Pharmaceuticals Co. |
Chronotherapeutic dosage forms
|
NZ545921A
(en)
*
|
2003-09-19 |
2009-09-25 |
Penwest Pharmaceuticals Co |
Delayed released dosage forms
|
TWI372066B
(en)
*
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
US7387793B2
(en)
|
2003-11-14 |
2008-06-17 |
Eurand, Inc. |
Modified release dosage forms of skeletal muscle relaxants
|
AU2004308419B2
(en)
*
|
2003-12-24 |
2011-06-02 |
Victory Pharma, Inc. |
Enhanced absorption of modified release dosage forms
|
NZ549838A
(en)
*
|
2004-03-26 |
2010-04-30 |
Eisai R&D Man Co Ltd |
Coated controlled-release preparation containing a gastric acid secretion inhibitor
|
US7404970B2
(en)
*
|
2004-04-13 |
2008-07-29 |
Konec, Inc. |
Pain relief composition, method to form same, and method to use same
|
EP1768668A2
(de)
|
2004-06-16 |
2007-04-04 |
Tap Pharmaceutical Products, Inc. |
Multi-ppi-dosierform
|
WO2006004774A2
(en)
*
|
2004-06-28 |
2006-01-12 |
Stanford University |
Laulimalide analogues as therapeutic agents
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
JP2008505124A
(ja)
|
2004-07-02 |
2008-02-21 |
アドバンシス ファーマスーティカル コーポレイション |
パルス送達用錠剤
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
US8747895B2
(en)
|
2004-09-13 |
2014-06-10 |
Aptalis Pharmatech, Inc. |
Orally disintegrating tablets of atomoxetine
|
US9884014B2
(en)
|
2004-10-12 |
2018-02-06 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions
|
NZ589750A
(en)
|
2004-10-21 |
2012-07-27 |
Aptalis Pharmatech Inc |
Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
|
US20060121112A1
(en)
*
|
2004-12-08 |
2006-06-08 |
Elan Corporation, Plc |
Topiramate pharmaceutical composition
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
US20070298098A1
(en)
*
|
2005-02-16 |
2007-12-27 |
Elan Pharma International Limited |
Controlled Release Compositions Comprising Levetiracetam
|
WO2006110807A1
(en)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International Limited |
Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
|
US9161918B2
(en)
|
2005-05-02 |
2015-10-20 |
Adare Pharmaceuticals, Inc. |
Timed, pulsatile release systems
|
ES2713062T3
(es)
|
2005-09-27 |
2019-05-17 |
Tissuetech Inc |
Preparaciones de membrana amniótica y composiciones purificadas y métodos de uso
|
US8187639B2
(en)
*
|
2005-09-27 |
2012-05-29 |
Tissue Tech, Inc. |
Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
|
US7994220B2
(en)
|
2005-09-28 |
2011-08-09 |
Cypress Bioscience, Inc. |
Milnacipran for the long-term treatment of fibromyalgia syndrome
|
EP1930030A1
(de)
*
|
2005-09-29 |
2008-06-11 |
Eisai R&D Management Co., Ltd. |
Puls-präparat mit verbesserten zerfallseigenschaften in vivo
|
CN101374507A
(zh)
*
|
2005-10-14 |
2009-02-25 |
H.隆德贝克有限公司 |
含有依他普仑和安非他酮的稳定药物制剂
|
JP2009511606A
(ja)
*
|
2005-10-14 |
2009-03-19 |
ハー・ルンドベック・アクチエゼルスカベット |
エスシタロプラムおよびブプロピオンの低用量の併用を用いる中枢神経系障害の治療方法
|
US8440695B2
(en)
*
|
2005-11-09 |
2013-05-14 |
St Jude Children's Research Hospital |
Use of chloroquine to treat metabolic syndrome
|
EA017290B1
(ru)
|
2005-11-28 |
2012-11-30 |
Домейн Раша Инвестментс Лимитед |
Композиции на основе ганаксолона
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
US8778924B2
(en)
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
CA2632039A1
(en)
*
|
2005-12-23 |
2007-06-28 |
Lek Pharmaceuticals D.D. |
Bursting pellets
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
US20090069275A1
(en)
*
|
2006-02-17 |
2009-03-12 |
Rocca Jose G |
Low flush niacin formulation
|
US9561188B2
(en)
|
2006-04-03 |
2017-02-07 |
Intellipharmaceutics Corporation |
Controlled release delivery device comprising an organosol coat
|
US8299052B2
(en)
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
DE602007009377D1
(de)
|
2006-05-30 |
2010-11-04 |
Intarcia Therapeutics Inc |
Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
|
KR101200728B1
(ko)
|
2006-08-09 |
2012-11-13 |
인타르시아 세라퓨틱스 인코포레이티드 |
삼투성 전달 시스템 및 피스톤 조립체
|
US20080090897A1
(en)
|
2006-08-11 |
2008-04-17 |
The Johns Hopkins University |
Compositions and methods for neuroprotectin
|
US8124598B2
(en)
*
|
2006-09-14 |
2012-02-28 |
Sharon Sageman |
7-keto DHEA for psychiatric use
|
EP2081435B1
(de)
|
2006-09-22 |
2016-05-04 |
Pharmacyclics LLC |
Hämmer der bruton-tyrosinkinase
|
US20100105738A1
(en)
*
|
2006-10-06 |
2010-04-29 |
Mitsuru Mizuno |
Extended release formulations of a proton pump inhibitor
|
JP2010510988A
(ja)
|
2006-11-28 |
2010-04-08 |
マリナス ファーマシューティカルズ |
ナノ粒子製剤とその製造方法およびその利用
|
CA2672602C
(en)
*
|
2006-12-18 |
2014-05-20 |
Electronic Dietary Foods Inc. |
Device for delivery of a substance
|
PT2099442E
(pt)
|
2006-12-26 |
2015-02-10 |
Pharmacyclics Inc |
Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
|
US20080187579A1
(en)
*
|
2007-02-01 |
2008-08-07 |
Pavan Bhat |
Extended-release dosage form
|
AU2008244523B2
(en)
|
2007-04-23 |
2012-02-16 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
US20100160274A1
(en)
*
|
2007-09-07 |
2010-06-24 |
Sharon Sageman |
7-KETO DHEA for Psychiatric Use
|
CA2699157A1
(en)
|
2007-09-10 |
2009-03-19 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
RU2013106514A
(ru)
*
|
2007-10-12 |
2015-03-10 |
Такеда Фармасьютикалз Норт Америка, Инк. |
Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи
|
EP2240155B1
(de)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
|
FR2930147B1
(fr)
*
|
2008-04-18 |
2013-02-08 |
Flamel Tech Sa |
Forme orale solide dotee d'un double profil de liberation
|
WO2010015029A1
(en)
|
2008-08-06 |
2010-02-11 |
Gosforth Centre (Holdings) Pty Ltd |
Compositions and methods for treating psychiatric disorders
|
MX2011002149A
(es)
|
2008-08-27 |
2011-04-05 |
Calcimedica Inc |
Compuestos que modulan el calcio intracelular.
|
AU2009311877C1
(en)
*
|
2008-11-07 |
2013-08-15 |
Samyang Holdings Corporation |
Pharmaceutical composition for release control of methylphenidate
|
US20100158905A1
(en)
|
2008-12-19 |
2010-06-24 |
Nuon Therapeutics, Inc. |
Combination therapy of arthritis with tranilast
|
JP5698683B2
(ja)
|
2009-03-09 |
2015-04-08 |
カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ |
治療薬のパルス放出組成物
|
US8603521B2
(en)
|
2009-04-17 |
2013-12-10 |
Pharmacyclics, Inc. |
Formulations of histone deacetylase inhibitor and uses thereof
|
ES2559029T3
(es)
|
2009-04-24 |
2016-02-10 |
Tissue Tech, Inc. |
Composiciones que contienen al complejo HC.HA y metodos de uso de las mismas
|
US8808257B2
(en)
*
|
2009-08-31 |
2014-08-19 |
Johnson & Johnson Vision Care, Inc. |
Methods and apparatus for pulsatile release of medicaments from a punctal plug
|
SI2462246T1
(en)
|
2009-09-28 |
2018-01-31 |
Intarcia Therapeutics, Inc. |
Fast-setting and / or cessation of substantially unchanged delivery of the product
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
JP5309262B2
(ja)
|
2009-12-02 |
2013-10-09 |
アプタリス ファーマ リミテッド |
フェキソフェナジン・マイクロカプセル及びそれを含む組成物
|
EP2558866B1
(de)
|
2010-04-15 |
2016-08-17 |
Tracon Pharmaceuticals, Inc. |
Potenzierung einer antikrebs-wirkung durch eine kombinationstherapie mit ber-pfad-hemmern
|
AU2011248579A1
(en)
|
2010-04-27 |
2012-11-29 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
WO2011139489A2
(en)
|
2010-04-27 |
2011-11-10 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
EP2568999B1
(de)
|
2010-05-11 |
2018-07-11 |
Mallinckrodt Ard Ip Limited |
Acth zur behandlung von amyotropher lateralsklerose
|
US9079891B2
(en)
|
2010-08-27 |
2015-07-14 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US8796416B1
(en)
|
2010-10-25 |
2014-08-05 |
Questcor Pharmaceuticals, Inc |
ACTH prophylactic treatment of renal disorders
|
GB201100786D0
(en)
|
2011-01-18 |
2011-03-02 |
Ems Sa |
Pharmaceutical compositions of immunosuppressants
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
US9526770B2
(en)
|
2011-04-28 |
2016-12-27 |
Tissuetech, Inc. |
Methods of modulating bone remodeling
|
CN109908099B
(zh)
|
2011-05-13 |
2021-10-29 |
Eb Ip希博里塔布斯有限责任公司 |
药物递送系统
|
US9682044B2
(en)
|
2011-06-10 |
2017-06-20 |
Tissuetech, Inc. |
Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
|
GB201111712D0
(en)
|
2011-07-08 |
2011-08-24 |
Gosforth Ct Holdings Pty Ltd |
Pharmaceutical compositions
|
SG2014014419A
(en)
|
2011-09-13 |
2014-07-30 |
Pharmacyclics Inc |
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
|
EP2586429A1
(de)
|
2011-10-26 |
2013-05-01 |
Freund Pharmatec Ltd. |
Arzneimittelabgabevorrichtung mit mehreren Einheiten für pulsierende oder verzögerte Freisetzung
|
EP3029463A1
(de)
|
2011-11-30 |
2016-06-08 |
DiagnosTear Ltd |
Trockenes-auge-diagnostik
|
US9089574B2
(en)
|
2011-11-30 |
2015-07-28 |
Emory University |
Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
|
US20140326056A1
(en)
*
|
2011-11-30 |
2014-11-06 |
D.E.S. Diagnostics Ltd |
Method for Quick Assessment of Osmolarity
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
BR112014020186A8
(pt)
|
2012-02-22 |
2017-07-11 |
Duchesnay Inc |
Formulação de doxilamina e piridoxina e/ou seus metabólitos ou sais
|
JP2015528001A
(ja)
|
2012-07-11 |
2015-09-24 |
ティッシュテック,インク. |
Hc−ha/ptx3複合体を含む組成物およびその使用方法
|
EP2900674B1
(de)
|
2012-09-28 |
2017-05-31 |
University of Washington through its Center for Commercialization |
Verbindungen und verfahren zur vorbeugung, behandlung und/oder schutz vor haarzelltod
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
TR201808077T4
(tr)
*
|
2012-11-19 |
2018-07-23 |
Follmann Gmbh & Co Kg |
Isı ile açılan stabil çekirdek/kabuk-mikrokapsüller.
|
US20150335571A1
(en)
*
|
2013-01-02 |
2015-11-26 |
Eatlittle Inc. |
Pseudobezoar-Based Intraluminal Gastrointestinal Transplant
|
GB201303781D0
(en)
|
2013-03-04 |
2013-04-17 |
Gauthier Pierre Pascal |
Oral timer device and method of using same
|
US10232018B2
(en)
|
2013-03-14 |
2019-03-19 |
Mallinckrodt Ard Ip Limited |
ACTH for treatment of acute respiratory distress syndrome
|
MX366760B
(es)
|
2013-07-22 |
2019-07-23 |
Duchesnay Inc |
Composición para la gestión de las náuseas y los vómitos.
|
WO2015054283A1
(en)
|
2013-10-08 |
2015-04-16 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
AU2014347357A1
(en)
|
2013-11-11 |
2016-06-16 |
Limoxifen B.V. |
Methods and pharmaceutical formulations for treatment of selective estrogen-receptor modulator-induced adverse drug reactions
|
US20150133516A1
(en)
|
2013-11-13 |
2015-05-14 |
Brian K. Adams |
Methods and Compositions for Treating ADHD
|
WO2015084998A1
(en)
|
2013-12-05 |
2015-06-11 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
ES2675002T3
(es)
*
|
2014-04-08 |
2018-07-05 |
Dow Global Technologies Llc |
Dispersión que comprende un éter de celulosa esterificado
|
TW201603818A
(zh)
|
2014-06-03 |
2016-02-01 |
組織科技股份有限公司 |
組成物及方法
|
TW201618783A
(zh)
|
2014-08-07 |
2016-06-01 |
艾森塔製藥公司 |
以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
CA2936741C
(en)
|
2014-10-31 |
2018-11-06 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
US10174275B2
(en)
|
2015-01-30 |
2019-01-08 |
Follmann Gmbh & Co. Kg |
Thermally opening stable core/shell microcapsules
|
CN107438613B
(zh)
|
2015-02-06 |
2020-08-25 |
华盛顿大学 |
用于预防或治疗感觉毛细胞死亡的化合物和方法
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
WO2016138025A2
(en)
|
2015-02-23 |
2016-09-01 |
Tissuetech, Inc. |
Apparatuses and methods for treating ophthalmic diseases and disorders
|
JP2018510138A
(ja)
|
2015-02-27 |
2018-04-12 |
カーテナ ファーマシューティカルズ,インク. |
Olig2活性の阻害
|
CN107735026A
(zh)
|
2015-05-01 |
2018-02-23 |
黛尔格诺斯蒂尔有限公司 |
测量泪液样品中泪液成分的方法
|
CN107847526A
(zh)
|
2015-05-20 |
2018-03-27 |
组织技术公司 |
用于预防上皮细胞的增殖和上皮‑间充质转换的组合物和方法
|
KR20240042548A
(ko)
|
2015-06-03 |
2024-04-02 |
인타르시아 세라퓨틱스 인코포레이티드 |
임플란트 배치 및 제거 시스템들
|
WO2017004526A1
(en)
|
2015-07-02 |
2017-01-05 |
University Of Louisville Research Foundation, Inc. |
EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER
|
US10975149B2
(en)
|
2015-12-16 |
2021-04-13 |
The Walter And Eliza Hall Institute Of Medical Research |
Inhibition of cytokine-induced SH2 protein in NK cells
|
TW201733600A
(zh)
|
2016-01-29 |
2017-10-01 |
帝聖工業公司 |
胎兒扶持組織物及使用方法
|
WO2017147146A1
(en)
|
2016-02-23 |
2017-08-31 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic trpv1 agonists
|
MA53353A
(fr)
|
2016-05-16 |
2021-06-09 |
Intarcia Therapeutics Inc |
Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
|
US10821105B2
(en)
|
2016-05-25 |
2020-11-03 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
GB2551980A
(en)
*
|
2016-06-30 |
2018-01-10 |
Commw Scient Ind Res Org |
Method and system for low level metal analysis of mineral samples
|
JP2019524816A
(ja)
|
2016-08-11 |
2019-09-05 |
オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics, Inc. |
てんかん性障害の処置のための方法および組成物
|
JP7028860B2
(ja)
|
2016-08-26 |
2022-03-02 |
カーテナ ファーマシューティカルズ,インク. |
Olig2活性の阻害
|
EP3565580B1
(de)
|
2017-01-03 |
2024-03-06 |
i2o Therapeutics, Inc. |
Kontinuierlicher verabreichung von exenatid und co-verabreichung von acetaminophen, ethinylestradiol oder levonorgestrel
|
WO2019039937A1
(en)
|
2017-08-21 |
2019-02-28 |
Stichting Vumc |
POLYTHERAPY FOR THE TREATMENT OF CANCER
|
CN112739345A
(zh)
|
2017-11-06 |
2021-04-30 |
斯奈普生物公司 |
Pim激酶抑制剂组合物,方法和其用途
|
US11685722B2
(en)
|
2018-02-28 |
2023-06-27 |
Curtana Pharmaceuticals, Inc. |
Inhibition of Olig2 activity
|
USD933219S1
(en)
|
2018-07-13 |
2021-10-12 |
Intarcia Therapeutics, Inc. |
Implant removal tool and assembly
|
WO2020023794A1
(en)
|
2018-07-27 |
2020-01-30 |
Concentric Analgesics, Inc. |
Pegylated prodrugs of phenolic trpv1 agonists
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
WO2020118142A1
(en)
|
2018-12-07 |
2020-06-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of pospartum depression
|
MX2021007925A
(es)
|
2018-12-31 |
2021-10-26 |
Biomea Fusion Llc |
Inhibidores irreversibles de la interaccion menina-mll.
|
WO2020190890A1
(en)
|
2019-03-15 |
2020-09-24 |
Unicycive Therapeutics Inc. |
Nicorandil derivatives
|
WO2021026124A1
(en)
|
2019-08-05 |
2021-02-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in treatment of status epilepticus
|
KR20220134529A
(ko)
|
2019-12-06 |
2022-10-05 |
마리누스 파마슈티컬스 인코포레이티드 |
복합 결절성 경화증의 치료에 사용하기 위한 가낙솔론
|
CA3202151A1
(en)
|
2020-12-16 |
2022-06-23 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin-mll interaction
|
CA3204457A1
(en)
|
2021-01-06 |
2022-07-14 |
Ben SESSA |
Mdma in the treatment of alcohol use disorder
|
WO2022238507A1
(en)
|
2021-05-11 |
2022-11-17 |
Awakn Ls Europe Holdings Limited |
Therapeutic aminoindane compounds and compositions
|
CA3221280A1
(en)
|
2021-06-03 |
2022-12-08 |
Arcadia Medicine, Inc. |
Enantiomeric entactogen compositions and methods of their use
|
WO2023018825A1
(en)
|
2021-08-11 |
2023-02-16 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
WO2023039240A1
(en)
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
WO2023086341A1
(en)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
US11945785B2
(en)
|
2021-12-30 |
2024-04-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as inhibitors of FLT3
|
WO2023139163A1
(en)
|
2022-01-19 |
2023-07-27 |
Awakn Ls Europe Holdings Limited |
1,3-benzodioxole esters and their therapeutic use
|
WO2023156565A1
(en)
|
2022-02-16 |
2023-08-24 |
Awakn Ls Europe Holdings Limited |
Bridged ring compounds and their therapeutic use as cns agents
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|